{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:21:08Z","timestamp":1762867268652},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11899-017-0413-y","type":"journal-article","created":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T01:46:57Z","timestamp":1507254417000},"page":"432-441","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"12","author":[{"given":"Kim-Hien T.","family":"Dao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,6]]},"reference":[{"issue":"3","key":"413_CR1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ajh.24284","volume":"91","author":"MA Elliott","year":"2016","unstructured":"\u2022\u2022 Elliott MA, Tefferi A. Chronic neutrophilic leukemia 2016: update on diagnosis, molecular genetics, prognosis, and management. Am J Hematol. 2016;91(3):341\u20139. Summary of expected changes to WHO CNL and aCML diagnostic criteria","journal-title":"Am J Hematol"},{"issue":"20","key":"413_CR2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"\u2022\u2022 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. Summary of expected changes to WHO CNL and aCML diagnostic criteria","journal-title":"Blood"},{"issue":"12","key":"413_CR3","first-page":"1696","volume":"90","author":"DP Mc Lornan","year":"2005","unstructured":"Mc Lornan DP, Percy MJ, Jones AV, Cross NC, Mc Mullin MF. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica. 2005;90(12):1696\u20137.","journal-title":"Haematologica"},{"issue":"7","key":"413_CR4","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.leu.2404240","volume":"20","author":"NC Lea","year":"2006","unstructured":"Lea NC, Lim Z, Westwood NB, Arno MJ, Gaken J, Mohamedali A, et al. Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia. Leukemia. 2006;20(7):1324\u20136.","journal-title":"Leukemia"},{"issue":"5","key":"413_CR5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ajh.20805","volume":"82","author":"S Kako","year":"2007","unstructured":"Kako S, Kanda Y, Sato T, Goyama S, Noda N, Shoda E, et al. Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. Am J Hematol. 2007;82(5):386\u201390.","journal-title":"Am J Hematol"},{"issue":"4","key":"413_CR6","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","volume":"106","author":"DP Steensma","year":"2005","unstructured":"Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106(4):1207\u20139.","journal-title":"Blood"},{"issue":"2","key":"413_CR7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12288-012-0203-6","volume":"30","author":"S Gajendra","year":"2014","unstructured":"Gajendra S, Gupta R, Chandgothia M, Kumar L, Gupta R, Chavan SM. Chronic neutrophilic leukemia with V617F JAK2 mutation. Indian Journal of Hematology & Blood Transfusion : An Official Journal of Indian Society of Hematology and Blood Transfusion. 2014;30(2):139\u201342.","journal-title":"Indian Journal of Hematology & Blood Transfusion : An Official Journal of Indian Society of Hematology and Blood Transfusion"},{"key":"413_CR8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-014-0077-1","volume":"7","author":"Y Cui","year":"2014","unstructured":"Cui Y, Li B, Gale RP, Jiang Q, Xu Z, Qin T, et al. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. J Hematol Oncol. 2014;7:77.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"413_CR9","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","volume":"122","author":"J Gotlib","year":"2013","unstructured":"Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013;122(10):1707\u201311.","journal-title":"Blood"},{"issue":"3","key":"413_CR10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","volume":"125","author":"CB Gambacorti-Passerini","year":"2015","unstructured":"\u2022\u2022 Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015;125(3):499\u2013503. First report of recurrent ETNK1 mutations in aCML","journal-title":"Blood"},{"issue":"3","key":"413_CR11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood-2014-11-609057","volume":"125","author":"O Kosmider","year":"2015","unstructured":"Kosmider O. Mutations of ETNK1 in aCML and CMML. Blood. 2015;125(3):422\u20133.","journal-title":"Blood"},{"key":"413_CR12","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/bcj.2014.94","volume":"5","author":"TL Lasho","year":"2015","unstructured":"Lasho TL, Finke CM, Zblewski D, Patnaik M, Ketterling RP, Chen D, et al. Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. Blood cancer journal. 2015;5:e275.","journal-title":"Blood cancer journal"},{"issue":"2","key":"413_CR13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2403562","volume":"19","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19(2):313\u20137.","journal-title":"Leukemia"},{"issue":"11","key":"413_CR14","first-page":"1566","volume":"91","author":"M Breccia","year":"2006","unstructured":"Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006;91(11):1566\u20138.","journal-title":"Haematologica"},{"issue":"4","key":"413_CR15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/jir.2012.0120","volume":"33","author":"BL Stein","year":"2013","unstructured":"Stein BL, Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research. 2013;33(4):145\u201353.","journal-title":"Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research"},{"issue":"6","key":"413_CR16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/ehm.11.63","volume":"4","author":"HC Hasselbalch","year":"2011","unstructured":"Hasselbalch HC. A new era for IFN-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol. 2011;4(6):637\u201355.","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"413_CR17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ajh.2830430416","volume":"43","author":"S Meyer","year":"1993","unstructured":"Meyer S, Feremans W, Cantiniaux B, Capel P, Huygen K, Dicato M. Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia. Am J Hematol. 1993;43(4):307\u20139.","journal-title":"Am J Hematol"},{"issue":"11","key":"413_CR18","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/jcp.55.11.862","volume":"55","author":"J Bohm","year":"2002","unstructured":"Bohm J, Schaefer HE. Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease. J Clin Pathol. 2002;55(11):862\u20134.","journal-title":"J Clin Pathol"},{"issue":"1","key":"413_CR19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000345851","volume":"130","author":"X Zhang","year":"2013","unstructured":"Zhang X, Pan J, Guo J. Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon alpha-2b. Acta Haematol. 2013;130(1):44\u20136.","journal-title":"Acta Haematol"},{"key":"413_CR20","first-page":"33","volume":"8","author":"MA Yassin","year":"2015","unstructured":"Yassin MA, Kohla S, Al-Sabbagh A, Soliman AT, Yousif A, Moustafa A, et al. A case of chronic neutrophilic leukemia successfully treated with pegylated interferon alpha-2a. Clinical Medicine Insights Case Reports. 2015;8:33\u20136.","journal-title":"Clinical Medicine Insights Case Reports"},{"issue":"4","key":"413_CR21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.20197","volume":"77","author":"IK Choi","year":"2004","unstructured":"Choi IK, Kim BS, Lee KA, Ryu S, Seo HY, Sul H, et al. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report. Am J Hematol. 2004;77(4):366\u20139.","journal-title":"Am J Hematol"},{"issue":"5","key":"413_CR22","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.3892\/ol.2015.3043","volume":"9","author":"J Shi","year":"2015","unstructured":"Shi J, Ni Y, Li J, Qiu H, Miao K. Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: a case report and literature review. Oncol Lett. 2015;9(5):2208\u201310.","journal-title":"Oncol Lett"},{"issue":"1","key":"413_CR23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3892\/ol.2015.3977","volume":"11","author":"H Jiang","year":"2016","unstructured":"Jiang H, Wu Z, Ren LI, Tao D, Tong H. Decitabine for the treatment of atypical chronic myeloid leukemia: a report of two cases. Oncol Lett. 2016;11(1):689\u201392.","journal-title":"Oncol Lett"},{"issue":"6","key":"413_CR24","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.3109\/10428194.2014.986477","volume":"56","author":"X Tong","year":"2015","unstructured":"Tong X, Li J, Zhou Z, Zheng D, Liu J, Su C. Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. Leukemia & Lymphoma. 2015;56(6):1911\u20133.","journal-title":"Leukemia & Lymphoma."},{"issue":"19","key":"413_CR25","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","volume":"368","author":"JE Maxson","year":"2013","unstructured":"\u2022\u2022 Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781\u201390. CSF3R -T618I first reported as a common oncogenic driver in CNL and some aCML","journal-title":"N Engl J Med"},{"issue":"2","key":"413_CR26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lrr.2014.07.002","volume":"3","author":"KH Dao","year":"2014","unstructured":"Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, et al. Significant clinical response to JAK1\/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Research Reports. 2014;3(2):67\u20139.","journal-title":"Leukemia Research Reports"},{"issue":"6","key":"413_CR27","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/leu.2014.39","volume":"28","author":"TL Lasho","year":"2014","unstructured":"Lasho TL, Mims A, Elliott MA, Finke C, Pardanani A, Tefferi A. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia. 2014;28(6):1363\u20135.","journal-title":"Leukemia"},{"issue":"5","key":"413_CR28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00277-014-2272-0","volume":"94","author":"E Ammatuna","year":"2015","unstructured":"Ammatuna E, Eefting M, van Lom K, Kavelaars FG, Valk PJ, Touw IP. Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. Ann Hematol. 2015;94(5):879\u201380.","journal-title":"Ann Hematol"},{"issue":"5","key":"413_CR29","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.3324\/haematol.2016.163089","volume":"102","author":"Z Nooruddin","year":"2017","unstructured":"Nooruddin Z, Miltgen N, Wei Q, Schowinsky J, Pan Z, Tobin J, et al. Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. Haematologica. 2017;102(5):e207\u2013e9.","journal-title":"Haematologica"},{"issue":"7","key":"413_CR30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00277-016-2664-4","volume":"95","author":"M Stahl","year":"2016","unstructured":"Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Ann Hematol. 2016;95(7):1197\u2013200.","journal-title":"Ann Hematol"},{"issue":"6","key":"413_CR31","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.3324\/haematol.2017.163790","volume":"102","author":"AS Gunawan","year":"2017","unstructured":"Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NCP, et al. Ruxolitinib, a potent JAK1\/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. Haematologica. 2017;102(6):e238\u2013e40.","journal-title":"Haematologica"},{"issue":"12","key":"413_CR32","first-page":"e414","volume":"7","author":"V Khanna","year":"2015","unstructured":"Khanna V, Pierce ST, Dao KH, Tognon CE, Hunt DE, Junio B, et al. Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia. Cureus. 2015;7(12):e414.","journal-title":"Cureus"},{"issue":"3","key":"413_CR33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ejh.12223","volume":"92","author":"Y Fu","year":"2014","unstructured":"Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, et al. Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic\/myeloproliferative neoplasms. Eur J Haematol. 2014;92(3):189\u201394.","journal-title":"Eur J Haematol"},{"issue":"3","key":"413_CR34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5045\/br.2013.48.3.178","volume":"48","author":"SN Lim","year":"2013","unstructured":"Lim SN, Lee JH, Lee JH, Kim DY, Kim SD, Kang YA, et al. Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic\/myeloproliferative neoplasms. Blood Research. 2013;48(3):178\u201384.","journal-title":"Blood Research"},{"issue":"12","key":"413_CR35","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.bmt.1704686","volume":"34","author":"M Koldehoff","year":"2004","unstructured":"\u2022\u2022 Koldehoff M, Beelen DW, Trenschel R, Steckel NK, Peceny R, Ditschkowski M, et al. Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant. 2004;34(12):1047\u201350. Only case series documenting outcomes after allogeneic stem cell transplantation in aCML","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"413_CR36","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","volume":"27","author":"A Pardanani","year":"2013","unstructured":"\u2022\u2022 Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27(9):1870\u20133. CSF3R -T618I reported as a highly specific oncogenic driver in CNL","journal-title":"Leukemia"},{"issue":"12","key":"413_CR37","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","volume":"99","author":"M Meggendorfer","year":"2014","unstructured":"\u2022 Meggendorfer M, Haferlach T, Alpermann T, Jeromin S, Haferlach C, Kern W, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica. 2014;99(12):e244\u20136. Compares specific mutations in CNL, aCML, and CMML","journal-title":"Haematologica"},{"issue":"17","key":"413_CR38","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","volume":"123","author":"SA Wang","year":"2014","unstructured":"\u2022 Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms. Blood. 2014;123(17):2645\u201351. Describes distinct features between aCML and MDS\/MPN unclassifiable in a large data set","journal-title":"Blood"},{"key":"413_CR39","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/asheducation-2015.1.264","volume":"2015","author":"KH Dao","year":"2015","unstructured":"Dao KH, Tyner JW. What\u2019s different about atypical CML and chronic neutrophilic leukemia? Hematology American Society of Hematology Education Program. 2015;2015:264\u201371.","journal-title":"Hematology American Society of Hematology Education Program"},{"issue":"3","key":"413_CR40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/10428190290012218","volume":"43","author":"G Dincol","year":"2002","unstructured":"Dincol G, Nalcaci M, Dogan O, Aktan M, Kucukkaya R, Agan M, et al. Coexistence of chronic neutrophilic leukemia with multiple myeloma. Leukemia & Lymphoma. 2002;43(3):649\u201351.","journal-title":"Leukemia & Lymphoma."},{"issue":"1","key":"413_CR41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/1097-0142(19900701)66:1<162::AID-CNCR2820660129>3.0.CO;2-Z","volume":"66","author":"GR Standen","year":"1990","unstructured":"Standen GR, Jasani B, Wagstaff M, Wardrop CA. Chronic neutrophilic leukemia and multiple myeloma. An association with lambda light chain expression. Cancer. 1990;66(1):162\u20136.","journal-title":"Cancer"},{"issue":"4","key":"413_CR42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/jcp.46.4.297","volume":"46","author":"GR Standen","year":"1993","unstructured":"Standen GR, Steers FJ, Jones L. Clonality of chronic neutrophilic leukaemia associated with myeloma: analysis using the X-linked probe M27 beta. J Clin Pathol. 1993;46(4):297\u20138.","journal-title":"J Clin Pathol"},{"issue":"4","key":"413_CR43","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3109\/10428194.2015.1094697","volume":"57","author":"B Stevens","year":"2016","unstructured":"Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, et al. Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. Leukemia & Lymphoma. 2016;57(4):927\u201334.","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"413_CR44","first-page":"693","volume":"14","author":"T Tursz","year":"1974","unstructured":"Tursz T, Flandrin G, Brouet JC, Seligmann M. Coexistence of a myeloma and a granulocytic leukemia in the absence of any treatment. Study of 4 cases. Nouv Rev Fr Hematol. 1974;14(6):693\u2013704.","journal-title":"Nouv Rev Fr Hematol"},{"issue":"7","key":"413_CR45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc.2017.40","volume":"17","author":"MWN Deininger","year":"2017","unstructured":"Deininger MWN, Tyner JW, Solary E. Turning the tide in myelodysplastic\/myeloproliferative neoplasms. Nat Rev Cancer. 2017;17(7):425\u201340.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"413_CR46","first-page":"28","volume":"38","author":"YJ Cui","year":"2017","unstructured":"Cui YJ, Jiang Q, Liu JQ, Li B, Xu ZF, Qin TJ, et al. The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia. Zhonghua xueyexue zazhi. 2017;38(1):28\u201332.","journal-title":"Zhonghua xueyexue zazhi"},{"issue":"7","key":"413_CR47","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ajh.24031","volume":"90","author":"MA Elliott","year":"2015","unstructured":"\u2022 Elliott MA, Pardanani A, Hanson CA, Lasho TL, Finke CM, Belachew AA, et al. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hematol. 2015;90(7):653\u20136. ASXL1 mutations and impact on prognosis in CNL","journal-title":"Am J Hematol"},{"issue":"9","key":"413_CR48","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","volume":"27","author":"M Meggendorfer","year":"2013","unstructured":"\u2022 Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, et al. SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27(9):1852\u201360. Survey of SETBP1 mutations among aCML and MDS\/MPN subtypes","journal-title":"Leukemia"},{"issue":"6","key":"413_CR49","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2016-10-695981","volume":"129","author":"JE Maxson","year":"2017","unstructured":"Maxson JE, Tyner JW. Genomics of chronic neutrophilic leukemia. Blood. 2017;129(6):715\u201322.","journal-title":"Blood"},{"key":"413_CR50","doi-asserted-by":"publisher","unstructured":"Patnaik MM, Barraco D, Lasho TL, Finke CM, Reichard K, Hoversten KP, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017;92(6):542-48. https:\/\/doi.org\/10.1002\/ajh.24722 .","DOI":"10.1002\/ajh.24722"},{"issue":"2","key":"413_CR51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOH.0000000000000114","volume":"22","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Elliott M, Pardanani A. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. Curr Opin Hematol. 2015;22(2):171\u20136.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"413_CR52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","volume":"45","author":"R Piazza","year":"2013","unstructured":"\u2022\u2022 Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18\u201324. First report of recurrent SETBP1 mutations in aCML","journal-title":"Nat Genet"},{"issue":"1","key":"413_CR53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminoncol.2011.11.004","volume":"39","author":"H Muramatsu","year":"2012","unstructured":"Muramatsu H, Makishima H, Maciejewski JP. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Semin Oncol. 2012;39(1):67\u201373.","journal-title":"Semin Oncol"},{"issue":"4","key":"413_CR54","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2015.337","volume":"30","author":"CC Mason","year":"2016","unstructured":"\u2022 Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. 2016;30(4):906\u201313. Survey of mutations observed in CMML","journal-title":"Leukemia"},{"issue":"22","key":"413_CR55","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","volume":"122","author":"AG Fleischman","year":"2013","unstructured":"\u2022\u2022 Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013;122(22):3628\u201331. Animal model confirming CSF3R -T618I mutation is oncogenic","journal-title":"Blood"},{"issue":"3","key":"413_CR56","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/1078-0432.CCR-14-3100","volume":"22","author":"JE Maxson","year":"2016","unstructured":"\u2022\u2022 Maxson JE, Luty SB, MacManiman JD, Paik JC, Gotlib J, Greenberg P, et al. The Colony-stimulating factor 3 receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2016;22(3):757\u201364. Animal model confirming CSF3R -T640N mutation is oncogenic","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"9","key":"413_CR57","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1074\/jbc.M113.508440","volume":"289","author":"JE Maxson","year":"2014","unstructured":"Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. J Biol Chem. 2014;289(9):5820\u20137.","journal-title":"J Biol Chem"},{"issue":"8","key":"413_CR58","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20090693","volume":"206","author":"I Plo","year":"2009","unstructured":"Plo I, Zhang Y, Le Couedic JP, Nakatake M, Boulet JM, Itaya M, et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med. 2009;206(8):1701\u20137.","journal-title":"J Exp Med"},{"key":"413_CR59","doi-asserted-by":"publisher","unstructured":"Zhang H, Means S, Schultz AR, Watanabe-Smith K, Medeiros BC, Bottomly D, et al. Unpaired extracellular cysteine mutations of CSF3R mediate gain or loss of function. Cancer Res. 2017;77(16):4258-67. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1052 .","DOI":"10.1158\/0008-5472.CAN-17-1052"},{"issue":"11","key":"413_CR60","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.4049\/jimmunol.167.11.6447","volume":"167","author":"F Dong","year":"2001","unstructured":"Dong F, Qiu Y, Yi T, Touw IP, Larner AC. The carboxyl terminus of the granulocyte colony-stimulating factor receptor, truncated in patients with severe congenital neutropenia\/acute myeloid leukemia, is required for SH2-containing phosphatase-1 suppression of Stat activation. Journal of Immunology (Baltimore, Md: 1950). 2001;167(11):6447\u201352.","journal-title":"Journal of Immunology (Baltimore, Md: 1950)"},{"issue":"3","key":"413_CR61","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2003-08-2913","volume":"104","author":"GJ Geijn van de","year":"2004","unstructured":"van de Geijn GJ, Gits J, Aarts LH, Heijmans-Antonissen C, Touw IP. G-CSF receptor truncations found in SCN\/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact. Blood. 2004;104(3):667\u201374.","journal-title":"Blood"},{"issue":"12","key":"413_CR62","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.exphem.2011.08.013","volume":"39","author":"G Kunter","year":"2011","unstructured":"Kunter G, Woloszynek JR, Link DC. A truncation mutant of Csf3r cooperates with PML-RARalpha to induce acute myeloid leukemia in mice. Exp Hematol. 2011;39(12):1136\u201343.","journal-title":"Exp Hematol"},{"key":"413_CR63","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Rohrabaugh S, Kesarwani M, Kincaid Z, Huber E, Leddonne J, Siddiqui Z, et al. Enhanced MAPK signaling is essential for CSF3R-induced leukemia. Leukemia. 2017;31(8):1770-78. https:\/\/doi.org\/10.1038\/leu.2016.376 .. MAPK signaling is involved in the pathogenesis of membrane-proximal CSF3R mutations.","DOI":"10.1038\/leu.2016.376"},{"issue":"2","key":"413_CR64","doi-asserted-by":"crossref","first-page":"e0171608","DOI":"10.1371\/journal.pone.0171608","volume":"12","author":"LH Shou","year":"2017","unstructured":"\u2022 Shou LH, Cao D, Dong XH, Fang Q, Wu Y, Zhang Y, et al. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: a meta-analysis. PLoS One. 2017;12(2):e0171608. Meta-analysis of SETBP1 mutations and impact on prognosis","journal-title":"PLoS One"},{"issue":"1","key":"413_CR65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.leu.2401993","volume":"15","author":"MA Elliott","year":"2001","unstructured":"\u2022\u2022 Elliott MA, Dewald GW, Tefferi A, Hanson CA. Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia. 2001;15(1):35\u201340. Pathologic and cytogenetic features of CNL before molecular profiling of CNL was achieved","journal-title":"Leukemia"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-017-0413-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0413-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0413-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T09:11:43Z","timestamp":1570180303000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-017-0413-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1007\/s11899-017-0413-y","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}